Compare Citius Pharmaceuticals Inc (CTXR) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Raymond James Financial, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while Raymond James Financial, Inc. trades at $180.63 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 1730.6× Citius Pharmaceuticals Inc's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | RJF | |
|---|---|---|
Market Cap | $20.01M | $34.63B |
Sector | Health | Financials |
52-Week High | $1.82 | $180.55 |
52-Week Low | $0.48 | $140.89 |
Enterprise Value | $16.23M | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
Raymond James Financial (RJF) trades at $180.34, up 0.7% for the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust revenue growth, with 2025 revenue at $13.84B and net income of $2.14B, supported by a P/E of 15.69 and net margin of 15.37%. Recent news highlights record Q3 2026 results and a golden cross formation, indicating positive momentum.
Outlook is positive due to consistent earnings outperformance and analyst buy ratings, but risks include volatile cash flows from investing activities and reliance on capital markets strength. The consensus price target of $183.75 suggests modest upside, with institutional interest shown by CalPERS' recent share acquisition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
